Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New mechanism to fight multi-resistant bacteria revealed

19.04.2017

In recent years scientists, clinicians and pharmaceutical companies have been struggling to find new antibiotics or alternative strategies against multi-drug resistant bacteria that represent nowadays a serious health problem. In a breakthrough study now published in PLOS Biology*, Isabel Gordo and her team at Instituto Gulbenkian de Ciência (IGC; Portugal) identified a compensatory mechanism in bacteria that might be used in the future as a new therapeutic target against multi-drug resistant bacteria.

As spread of multi-drug resistant bacteria increases, it is important to understand how are they being maintained in populations. Antibiotics target essential bacteria cellular functions. However, bacteria can evolve and become resistant to these drugs by acquiring mutations in genes involved in those functions.


These are E. coli bacteria with different antibiotic resistances (in yellow and blue) evolving.

Credit: Jorge Sousa, IGC.

This comes at a cost for bacteria, as most drug resistant mutations are prejudicial in the absence of the antibiotic. To overcome this, bacteria can acquire additional compensatory mutations. How these compensatory mutations evolve in multi-drug resistant bacteria was completely unknown, and was what Isabel Gordo's team proposed to study now.

Previous results from Isabel Gordo's laboratory showed that genetic interactions between resistance mutations are frequent and are the driver for multi-resistance. Now, the researchers showed that the pace of the compensatory adaptation in multi-drug resistant Escherichia coli (E. coli) strains is faster than for strains carrying a single resistance mutation.

Most importantly, they were able to identify the key proteins involved in the compensatory mechanism of multi-drug resistant bacteria. These results came from the analysis of E. coli strains with single resistance to rifampicin and to streptomycin antibiotics, and strains with resistance to both antibiotics, grown in antibiotic-free media.

"If we use a very simplistic metaphor and compare bacteria with a car, we would say that many mutations that confer resistance to streptomycin affect the motor of the cell that drives the production of proteins (the ribosome), whereas resistances to rifampicin come from mutations in the accelerator of that motor (a protein called RNA polymerase).

We now discovered that the compensatory mechanism of multi-drug resistant E. coli encompasses mutations in the 'clutch', i.e. in proteins that link the cell's 'motor' with the 'accelerator'", explains Isabel Gordo. The IGC researcher further adds: "If we can block the proteins now identified we may be able to kill multi-drug resistant bacteria, since we would be eliminating this compensatory mechanism that favours their growth in the population."

The research team predicts that the mechanism now discovered might be generally used in several other multi-drug resistances, since antibiotics target the same cellular mechanisms. Hence, the proteins now identified can be good candidate targets for the design of therapies against multi-drug resistant bacteria.

###

This study was conducted at Instituto Gulbenkian de Ciência and funded by European Research Council and the Fundação para a Ciência e a Tecnologia (Portugal).

*Moura de Sousa J, Balbontin R, Durão P, Gordo I (2017) Multidrug-resistant bacteria compensate for the epistasis between resistances. PLoS Biol 15(4): e2001741. https://doi.org/10.1371/journal.pbio.2001741

Ana Mena | EurekAlert!

More articles from Life Sciences:

nachricht Rochester scientists discover gene controlling genetic recombination rates
23.04.2018 | University of Rochester

nachricht One step closer to reality
20.04.2018 | Max-Planck-Institut für Entwicklungsbiologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Structured light and nanomaterials open new ways to tailor light at the nanoscale

23.04.2018 | Physics and Astronomy

On the shape of the 'petal' for the dissipation curve

23.04.2018 | Physics and Astronomy

Clean and Efficient – Fraunhofer ISE Presents Hydrogen Technologies at the HANNOVER MESSE 2018

23.04.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>